Celadon Pharmaceuticals PLC Finance Update
12 Februar 2025 - 8:00AM
RNS Regulatory News
RNS Number : 7521W
Celadon Pharmaceuticals PLC
12 February 2025
Celadon Pharmaceuticals
Plc
("Celadon", the "Group" or the
"Company")
Finance Update
London, 12 February 2025 -
Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical
company focused on the development, production and sale of
breakthrough cannabis-based medicines, provides an update on its
financial position.
The Company is pleased to announce
that it has received the final £103k from its £1.0m draw down
request, under its Committed Credit Facility. The Company has also
received a £389k tax credit from a R&D claim for the year ended
December 2022. The tax credit was held on balance sheet as a
deferred tax asset.
The Company continue to explore
further capital opportunities.
Enquiries:
|
|
|
|
Celadon Pharmaceuticals Plc
|
|
|
James Short
|
Via Canaccord Genuity
Limited
|
|
Canaccord Genuity Limited (Nominated Adviser and
Broker)
|
|
|
Bobbie Hilliam / Andrew
Potts
|
+44 (0)20 7523 8000
|
|
|
|
|
Global Investment Strategy UK Limited (Joint
Broker)
James Sheehan
|
+44 (0)20 7048 9400
|
|
|
|
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a
UK-based pharmaceutical company focused on
the development, production and sale of breakthrough cannabis-based
medicines. Its primary focus is on
improving quality of life for chronic pain sufferers, as well as
exploring the potential of cannabis-based medicines for other
conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP
approved and comprises indoor hydroponic cultivation, proprietary
GMP extraction and an analytical and R&D laboratory. Celadon's
Home Office licence allows for the commercial supply of its
pharmaceutical-grade cannabis product. The Group owns an approved
clinical trial using cannabis-based medicinal products to treat
chronic pain in the UK. Celadon also has a minority interest in
early-stage biopharma Kingdom Therapeutics, which is developing a
licensed cannabinoid medicine to treat children with Autism
Spectrum Disorder.
For further information please visit
our website www.celadonpharma.com
This announcement contains inside
information for the purposes of article 7 of the Market Abuse
Regulation (EU) 596/2014 as amended by regulation 11 of the Market
Abuse (Amendment) (EU Exit) Regulations 2019/310. With the
publication of this announcement, this information is now
considered to be in the public domain.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
UPDSFMFWFEISELE
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
Von Mär 2025 bis Apr 2025
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
Von Apr 2024 bis Apr 2025
